Paradis C et al. Atteinte neurologique définitive dans un contexte de consommation intraveineuse de méthcathinone (éphédrone). Toxac 2022. https://doi.org/10.1016/j.toxac.2022.09.001
Kerckhove N, Delage N, Bertin C, Kuhn E, Cantagrel N, Vigneau C, Delorme J, Lambert C, Pereira B, Chenaf C, Authier N; Poma Network. Cross-sectional study of the prevalence of prescription opioids misuse in French patients with chronic non-cancer pain: An update with the French version of the POMI scale. Front Pharmacol. 2022 Sep 5;13:947006. doi: …
Carton L, Icick R, Weibel S, Dematteis M, Kammerer E, Batisse A, Rolland B. What is the potential for abuse of lisdexamfetamine in adults? A preclinical and clinical literature review and expert opinion. Expert Rev Clin Pharmacol. 2022 Aug 18:1-5. doi: 10.1080/17512433.2022.2112950. Epub ahead of print. PMID: 35959655.
Goncalves R, Peyré A, Castaing N, Beeken T, Olivier S, Combe P, Miremont-Salamé G, Titier K, Molimard M, Daveluy A. Minors and young adult’s hospitalizations after « chimique » consumption in Mayotte Island: Which substances are involved? Therapie. 2022 Aug 1:S0040-5957(22)00124-X. doi: 10.1016/j.therap.2022.07.007. Epub ahead of print. PMID: 36064627.
Laforgue EJ, Rousselet M, Claudon A, Aquizerate A, Jolliet P, Istvan M, Victorri-Vigneau C. Did the New French Regulation of Zolpidem Decrease the Problematic Consumption of Zolpidem? A Field Study among Users. Int J Environ Res Public Health. 2022 Jul 22;19(15):8920. doi: 10.3390/ijerph19158920. PMID: 35897285; PMCID: PMC9331950.
Eiden C, Roy S, Malafaye N, Lehmann M, Peyrière H. Ten-year trends in hospitalizations related to cocaine abuse in France. Fundam Clin Pharmacol. 2022 Jul 8. doi: 10.1111/fcp.12815. Epub ahead of print. PMID: 35801616.
Dumoulin C, Ong N, Ramaroson H, Létinier L, Miremont-Salamé G, Gilleron V, Daveluy A, Perino J. Hospitalisations après consommation de substances psychoactives pendant la pandémie de Covid-19 [Hospitalizations after substance use during the COVID-19 pandemic]. Therapie. 2022 Jun 30:S0040-5957(22)00108-1. French. doi: 10.1016/j.therap.2022.06.003. Epub ahead of print. PMID: 35908997; PMCID: PMC9329723.
Communiqué de l’Association Française des Centres d’Addictovigilance du 23 juin 2022. L’Association Française des Centres d’Addictovigilance alerte sur les caractéristiques cliniques et l’ampleur des complications sanitaires graves avec l’usage non médical du protoxyde d’azote. Lisez le communiqué complet ci-dessous :
Revol B, Lapeyre-Mestre M, Fouilhé Sam-Laï N, Jouanjus E. Association between NMDAR antagonists, drug abuse and dependence: A disproportionality analysis from the WHO pharmacovigilance database. Br J Clin Pharmacol. 2022 Jun 4. doi: 10.1111/bcp.15430. Epub ahead of print. PMID: 35665950.
Roy S, Charreteur R, Peries M, Kheloufi F, Eiden C, Nagot N, Donnadieu-Rigole H, Micallef J, Peyrière H. Abuse and misuse of second-generation antipsychotics: an analysis using VigiBase TM , the World Health Organisation pharmacovigilance database. Br J Clin Pharmacol. 2022 May 27. doi: 10.1111/bcp.15420. Epub ahead of print. PMID: 35633029.